MDCLF (Medincell) Capex-to-Revenue: 0.00 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MDCLF Medincell SA MDCLF
77 GF Score
Price $34.39
GF Value $27.51
! 5 Warning Signs
View Full Analysis

What is Medincell Capex-to-Revenue?

Medincell MDCLF +393.00% 77 Capex-to-Revenue is 0.00 as of Mar. 2026. GuruFocus rates MDCLF with a GF Score™ of 77/100 and a GF Value™ of $27.51. The stock has 5 warning signs investors should review.

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue.

Medincell's Capital Expenditure for the six months ended in Mar. 2026 was $0.00 Mil. Its Revenue for the six months ended in Mar. 2026 was $9.15 Mil.

Hence, Medincell's Capex-to-Revenue for the six months ended in Mar. 2026 was 0.00.

Medincell  (OTCPK:MDCLF) Capex-to-Revenue Explanation

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue. The ratio shows how aggressively the company reinvests its revenue back into productive assets. However, a high ratio potentially indicates that the company has invested too much in innovation and infrastructure, taking up funds that could be used to boost productivity and increase revenue. Therefore, a high Capex to Revenue Ratio could be a positive or a negative sign depending on how effectively a company converts those investments into future earnings.

Medincell Capex-to-Revenue Related Terms

Medincell Capex-to-Revenue Historical Data

* Premium members only.

The historical data trend for Medincell's Capex-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Medincell Capex-to-Revenue Chart

Medincell Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Capex-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.48 0.10 0.13 0.07 0.00

Medincell Semi-Annual Data
Mar16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25 Mar26
Capex-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.37 0.06 0.07 0.07 0.00

MDCLF vs VRTX, REGN, ALNY: Capex-to-Revenue Comparison

For the Biotechnology subindustry, Medincell's Capex-to-Revenue, along with its competitors' market caps and Capex-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Medincell Capex-to-Revenue vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Medincell's Capex-to-Revenue distribution charts can be found below:

* The bar in red indicates where Medincell's Capex-to-Revenue falls into.


MDCLF
77GF Score
Medincell SA MDCLF
Capex-to-Revenue is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Medincell Capex-to-Revenue Calculation

Medincell's Capex-to-Revenue for the fiscal year that ended in Mar. 2026 is calculated as

Capex-to-Revenue=- Capital Expenditure / Revenue
=- (0) / 22.564
=0.00

Medincell's Capex-to-Revenue for the quarter that ended in Mar. 2026 is calculated as

Capex-to-Revenue=- Capital Expenditure / Revenue
=- (0) / 9.145
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Capex-to-Revenue →
What does a Capex-to-Revenue of 0.00 mean?
Medincell (MDCLF) has a Capex-to-Revenue of 0.00 as of Mar. 2026. Capex to Revenue ratio measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue. View historical data on Medincell and its competitors.
Is Medincell's Capex-to-Revenue too high?
Medincell's current Capex-to-Revenue is 0.00. Overall, Medincell has a GF Score™ of 77/100, reflecting its overall financial health beyond just this single metric.
How does Medincell's Capex-to-Revenue compare to VRTX and REGN?
Medincell's Capex-to-Revenue of 0.00 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Capex-to-Revenue for a Biotechnology company?
A good Capex-to-Revenue depends on the Biotechnology industry context. However, Capex-to-Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Capex-to-Revenue mean?
A high Capex-to-Revenue can signal that a stock is expensive relative to its fundamentals. Capex to Revenue ratio measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue. View historical data on Medincell and its competitors. Medincell's current Capex-to-Revenue is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medincell stock overvalued right now?
Medincell (MDCLF) has a current Capex-to-Revenue of 0.00. The stock's GF Value™ is $27.51, compared to a current price of $34.39 — trading 25% above its estimated fair value. The current Capex-to-Revenue is 0.00. Medincell's overall GF Score™ is 77/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Capex-to-Revenue calculated?
Capex-to-Revenue is calculated from a company's financial statements. For Medincell (MDCLF), the current Capex-to-Revenue is 0.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Medincell (MDCLF) Overvalued in 2026?

Based on GuruFocus' analysis, Medincell stock appears to be overvalued. The current stock price of $34.39 is trading 25% above its estimated GF Value™ of $27.51.

Key valuation signals for MDCLF:

  • Capex-to-Revenue: 0.00
  • GF Value™: $27.51 vs. price of $34.39 (25% above fair value)
  • GF Score™: 77/100 with 5 warning signs

No single metric tells the full story. See the MDCLF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Medincell Business Description

Address 3 rue des Freres Lumiere, Jacou, FRA, 34830
Medincell SA is a technology-based pharmaceutical firm, aims to optimise the efficiency of medical treatments and make them accessible geographically. The company's product portfolio uses BEPO-patented technology to develop controlled, long-acting injectable medical treatments for a number of therapeutic fields. The firm has a single operating segment: ongoing research and development on processes that use biodegradable polymers to enable the controlled and prolonged release of the active principles of drugs into the human body and animals by means of injection.
77GF Score

Get the complete analysis for MDCLF

Capex-to-Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$34.39
Price
$27.51
GF Value